Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.49 |
| ▸ | ELAVL1 | Q15717 | 2/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3044328 | 0.81 | ELAVL1 (0.51) | HTR6ELAVL1CA12CA1CA2 | |
| SCHEMBL3046174 | 0.78 | HTR6 (0.47) | HTR6 | |
| SCHEMBL2887000 | 0.77 | MEN1 (0.60) | HTR6 | |
| SCHEMBL1651879 | 0.77 | HTR6 (0.74) | HTR6ELAVL1CA12CA1CA2 | |
| SCHEMBL2887045 | 0.76 | KDM4E (0.45) | HTR6 | |
| SCHEMBL19737552 | 0.72 | HTR6 (0.55) | HTR6ELAVL1CA12CA1CA2 | |
| SCHEMBL13959826 | 0.70 | ABCB1 (0.55) | ABCB1DRD2 | |
| SCHEMBL3036049 | 0.70 | ABCB1 (0.52) | ABCB1DRD2 | |
| SCHEMBL17927509 | 0.69 | HTR6 (0.71) | HTR6 | |
| SCHEMBL19737472 | 0.69 | HTR6 (0.66) | HTR6DRD2HTR7HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820630-B2 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-26 | — | — | US | disclosed |
| US-20100009900-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | BEAVERS MARY PAT | 2010-01-14 | — | — | US | disclosed |
| US-20090105164-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | BEAVERS MARY PAT | 2009-04-23 | — | — | US | disclosed |
| US-7511022-B2 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-31 | — | — | US | disclosed |
| US-20060293251-A1 | Substituted indazole-O-glucosides | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-28 | — | — | US | disclosed |
| US-7129220-B2 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA N.V (BE) | 2006-10-31 | — | — | US | disclosed |
| US-20050037981-A1 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009900-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | GPR119, PYGL, IAPP | HTR6 100/4885ELAVL1 2641/4885ABCB1 2246/4885 |
| US-20090105164-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | GPR119, PYGL, IAPP | HTR6 100/4885ELAVL1 2641/4885ABCB1 2246/4885 |
| US-20050037981-A1 | Substituted indole-O-glucosides | GPR119, PYGL, IAPP | HTR6 100/4885ELAVL1 2641/4885ABCB1 2246/4885 |
| US-20060293251-A1 | Substituted indazole-O-glucosides | GPR119, PYGL, GYS2 | HTR6 946/4885ELAVL1 3860/4885ABCB1 839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.